Semaglutide Weight Management and Cardiovascular Risk Reduction
GLP-1 diabetes: Key take-aways:
GLP-1 RA's have demonstrated several benefits and are recommended as first line
treatment for some people with T2D in international treatment guidelines
In the phase 2 trial, CagriSema showed improved reduction of HbA1c and of body
weight as well as longer time in range vs monocomponents
CagriSema appeared to have a safe and well-tolerated profile. Phase 3 in T2D is
expected to be initiated during H2 of 2023
Based on the efficacy profile in PIONEER PLUS, oral semaglutide 25 and 50 mg may
provide the option for patients to progress to higher doses if additional glycaemic
control or weight loss is needed
GLP-1 RA: Glucagon like peptide-1 receptor agonist; T2D: Type 2 diabetes
Note: CagriSema is a fixed dose combination of injectable cagrilintide 2.4 mg and injectable semaglutide 2.4 mg
C
O
O
O
novo nordiskView entire presentation